Ocrelizumab (Ocrevus)

Ocrevus (ocrelizumab) is covered only for adults (≥18) with FDA‑approved relapsing forms of MS or primary progressive MS; off‑label compendial uses are not approved. Coverage requires documentation of age and diagnosis, no active infection including hepatitis B, no concurrent disease‑modifying MS agents, no live vaccines during therapy, and evidence of clinical benefit for 12‑month initial and renewal approvals.

"Ocrevus is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS)."

Sign up to see full coverage criteria, indications, and limitations.